Clinical Trials Logo

MSI-H Tumors clinical trials

View clinical trials related to MSI-H Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT03607890 Recruiting - Clinical trials for Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Start date: November 16, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.